[Advances on driver oncogenes of non-small cell lung cancer]

Jianguo Zhao, Jianping Xiong, Jianguo Zhao, Jianping Xiong

Abstract

Adenocarcinoma and squamous cell carcinoma are the most common histological types of non-small cell lung cancer (NSCLC). Several molecular alterations have been defined as "driver oncogenes" responsible for both the initiation and maintenance of the malignancy. With next-generation sequencing (NGS) which having multiple and high-throughput genotyping is wildly used and promoted, make the detection of patients gene composition from a tiny tumor biopsy specimens become possible, initiate the clinical studies based on the genetic characteristics, and promote the progress of molecular typing in NSCLC. So far, about 60% of lung adenocarcinoma has been found harbouring driver oncogenes, the rate of lung squamous cell carcinoma driven genes detection has gradually improved, in which epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), fibroblast growth factor receptor 1 (FGFR1), phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) and so on plays important roles. The currently effective targeted therapies is mainly used against EGFR, ALK, etc. In this review, we will report the mainly advances on some latest driver mutations of NSCLC.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistic, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138.
    1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–1380. doi: 10.1056/NEJMra0802714.
    1. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801. doi: 10.6004/jnccn.2010.0056.
    1. Ansorge WJ. Next-generation DNA sequencing techniques. N Biotechnol. 2009;25(4):195–203. doi: 10.1016/j.nbt.2008.12.009.
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699.
    1. Zhou CC, Wu YL, Chen G, et al. Updated efficacy and quality-of-lifeI (QoL) analysesn in OPTIMAL, a phase Ⅲ, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut +) advanced non-small cell lung cancer (NSCLC) J Clin Oncol. 2011;29(18s):abstr7520.
    1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703. doi: 10.1056/NEJMoa1006448.
    1. Gandhi L, Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res. 2012;18(14):3737–3742. doi: 10.1158/1078-0432.CCR-11-2393.
    1. Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–189. doi: 10.1016/j.lungcan.2013.07.025.
    1. Kris MG, Johnson BE, Kwiatkowski DG, et al. Identification of driver mutations in tumor specimens from 1, 000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC) J Clin Oncol. 2011;29(18s):abstr7506.
    1. Yang PC, Shi Y, Au J, et al. Molecular epidemiological prospective study of EGFR mutation from Asian patients (pts) with advanced adenocarcinoma (PIONNER) J Clin Oncol. 2012;30(18s):abstr1524.
    1. Fabrice Barlesi, Helene Blons, Michele Beau-Faller, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10000 non-small cell lung cancer (NSCLC) patients (pts) J Clin Oncol. 2013;31(18s):abstr8000.
    1. Feldman RA, Wang LH, Hanafusa H, et al. Avian sarcoma virus UR2 encodes a transforming protein which is associated with a unique protein kinase activity. . J Virol. 1982;42(2):228–236.
    1. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870. doi: 10.1200/JCO.2011.35.6345.
    1. Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24(9):2364–2370. doi: 10.1093/annonc/mdt220.
    1. Ou SH1, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942–946. doi: 10.1097/JTO.0b013e31821528d3.
    1. Lipson D, Capelletti M, Yelensky, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–384. doi: 10.1038/nm.2673.
    1. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203. doi: 10.1016/j.cell.2007.11.025.
    1. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381. doi: 10.1038/nm.2658.
    1. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869–873. doi: 10.1038/nature09208.
    1. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012;7(5):924–933. doi: 10.1097/JTO.0b013e31824cc334.
    1. Drilon A, Rekhtman N, Ladanyi M, et al. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012;13(10):e418–e426. doi: 10.1016/S1470-2045(12)70291-7.
    1. Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32(2):121–128. doi: 10.1200/JCO.2013.50.8556.
    1. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–1242. doi: 10.1038/ng.465.
    1. Hussenet T, du Manoir S. SOX2 in squamous cell carcinoma amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle. 2010;9(8):1480–1486. doi: 10.4161/cc.9.8.11203.
    1. Gandara DR1, Li T, Lara PN Jr, et al. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012;13(5):321–325. doi: 10.1016/j.cllc.2012.05.004.
    1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol. 2003;21(12):2237–2246. doi: 10.1200/JCO.2003.10.038.
    1. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2006;24(24):3831–3837. doi: 10.1200/JCO.2006.05.8073.
    1. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14(10):953–961. doi: 10.1016/S1470-2045(13)70355-3.
    1. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase Ⅲ trial. Lancet. 2009;373(9674):1525–1531. doi: 10.1016/S0140-6736(09)60569-9.
    1. Kim ES, Mauer AM, William WN Jr, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009;115(8):1713–1722. doi: 10.1002/cncr.v115:8.
    1. Pearson R, Kolesar JM. Targeted therapy for NSCLC: ALK inhibition. J Oncol Pharm Pract. 2012;18(2):271–274. doi: 10.1177/1078155211417477.
    1. Shaw AT, Yeap BY, Solomon BJ, et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol. 2011;29(15s):abstr7507.
    1. Kim DW, Ahn M, Yang P, et al. Updated results of a Global Phase Ⅱ Study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) Ann Oncol. 2012;23(9s):s402.
    1. Shaw AT, Kim DW, Nakagawa k, et al. Phase Ⅲ study of crizotinib versus pemetrexed or doctaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC)(PROFILE 1007) Ann Oncol. 2012;23(9s):s21.
    1. Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase Ⅲ study (PROFILE 1014) J Clin Oncol. 2014;32(15s):abstr8002.
    1. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangment. J Clin Oncol. 2012;30(15s):abstr7508.
    1. Ou SI, Camidge DR, Engelman J, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangment. Ann Oncol. 2012;23(9s):S389.
    1. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93.
    1. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351. doi: 10.1371/journal.pone.0020351.
    1. Nogova L, Sequist LV, Cassier PA, et al. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol. 2014;32(15s):abstr8034.
    1. Ignacio GL, David SH, Filip J, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012;7(5):e38033. doi: 10.1371/journal.pone.0038033.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren